Clinical trials: Skin Inflammation
Phototoxicity
Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream
This trial is a 4-day, randomized study to determine the phototoxic potential of MC2-01 Cream when topical application to healthy skin is followed by light exposure.
- Trial name
- NCT03892564
- Testing
- MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- MC2 Therapeutics
Itching Symptoms, Xerotic Dermatitis
Xerotic Dermatitis in Aged People
The purpose of the study is to assess the the effect of the study product on itching symptoms associated with xerotic dermatitis in aged population
- Trial name
- NCT01806935
- Testing
- DC086
- Where
- 14 sites in France
- Volunteers
- 442 people
- Sponsor
- Pierre Fabre Medical Devices
Atopic Dermatitis
CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis
This is a Phase 3, randomized, double-blinded, placebo-controlled trial in patients, ≥12 years of age who weigh ≥40 kg, and are diagnosed with moderate-to-severe AD.
- Trial name
- NCT05614817
- Testing
- CBP-201
- Sponsor
- Connect Biopharm LLC
Atopic Dermatitis
A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 injection in the treatment of patients with moderate to severe atopic dermatitis.
- Trial name
- NCT06383468
- Testing
- AK120
- Where
- 59 sites in China
- Volunteers
- 420 people
- Sponsor
- Akeso
Healthy
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see: how the body processes the study medicine and if food affects the amount of study…
- Trial name
- NCT06686797
- Testing
- PF-08049820
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Pfizer
Contact Dermatitis
Clinical Evaluation of Lyral® Dose Response Study
The purpose of this study is to determine optimal allergen dose as the lowest concentration eliciting positive reactions in 70-90% of subjects.
- Trial name
- NCT02028182
- Testing
- Lyral®
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Allerderm
Healthy Volunteer
Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects
Skin Irritation and Phototoxicity Study of KX01 Ointment 1% in Japanese healthy male subjects
- Trial name
- NCT05245578
- Testing
- KX01 ointment 1%
- Where
- Japan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- PharmaEssentia
Atopic Dermatitis, Asthma
A Clinical Study to Evaluate SM17 in Healthy Participants
This is a phase I study in Chinese healthy adult volunteer participants. It aims to evaluate the safety, tolerability, PK profile and immunogenicity of a single dose of SM17 SC in healthy Chinese adult participants.
- Conditions
- Atopic Dermatitis, Asthma, Inflammatory Bowel Disease
- Trial name
- NCT07466940
- Testing
- SM17
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SinoMab BioScience Ltd
Atopic Dermatitis
A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis
The objective of this study was to evaluate the safety and efficacy of multiple doses of upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02925117
- Testing
- Upadacitinib
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- AbbVie
Photoallergy
To Test for Photo Allergy Reaction of Sunscreens
The primary objective of this tudy was to evaluate the potential of photoallergy of of sun care products Sun Protection Factor (SPF) 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104 application compared to that of a negative…
- Trial name
- NCT02872220
- Testing
- SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519)
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bayer
Dermatitis
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
- Trial name
- NCT01259323
- Testing
- REGN668
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis (AD)
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
- Trial name
- COMPASS 2-AD (NCT07105488)
- Testing
- BFB759
- Where
- 88 sites in United States, Bulgaria and 5 more
- Volunteers
- 225 people
- Sponsor
- Bluefin Biomedicine, Inc.
Dermatitis Atopic
A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
The purpose of this study is to evaluate the skin irritation potential of PF-07038124 ointment and vehicle (placebo) in Part A following multiple-doses applied topically to healthy participants.
- Trial name
- NCT04135560
- Testing
- PF-07038124 and Vehicle, PF-07038124 or vehicle
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pfizer
Staphylococcal Skin Infections, Wounds and Injuries
A Study for Patients With Complicated Skin and Skin Structure Infections
Two Phase III trials to demonstrate the efficacy and safety of oritavancin in the treatment of complicated skin and skin structure infections (cSSSI) have been completed.
- Conditions
- Staphylococcal Skin Infections, Wounds and Injuries, Abscess, Cellulitis
- Trial name
- SIMPLIFI (NCT00514527)
- Testing
- oritavancin
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 294 people
- Sponsor
- Targanta Therapeutics Corporation
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study.
- Trial name
- NCT04921969
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis, Dermatitis, Atopic
Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis
The purpose of this study is to investigate the clinical efficacy of 3% (w/w) GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI) assessment of…
- Trial name
- NCT00354510
- Testing
- GW842470X cream
- Where
- 13 sites in Germany, Netherlands
- Volunteers
- 190 people
- Sponsor
- GlaxoSmithKline
Prurigo Nodularis
A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
- Trial name
- NCT02196324
- Testing
- serlopitant
- Where
- 15 sites in Germany
- Volunteers
- 128 people
- Sponsor
- Vyne Therapeutics Inc.
Giant Cell Arteritis
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
This study was designed to evaluate the efficacy and safety of secukinumab compared to placebo to maintain disease remission up to 28 weeks including corticosteroid tapering, as well as up to 1 year (52 weeks) in patients with…
- Trial name
- TitAIN (NCT03765788)
- Testing
- Secukinumab 300 mg, s.c., Prednisolone
- Where
- 11 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Dermatitis, Atopic
Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis
The study shall explore whether treatment of atopic dermatitis is equally effective with respect to a marketed medical device and a new medical device.
- Trial name
- Phoenix II (NCT01948869)
- Testing
- Phoenix II (BAY81-2996), Phoenix I (BAY81-2996)
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Bayer
Atopic Dermatitis
POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections.
- Trial name
- ADAMANT (NCT05932654)
- Testing
- BSI-045B
- Where
- 17 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biosion, Inc.